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Background: Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) caused by a 
TMEM43 p.S358l variant is a particularly lethal subset of the disease found in high incidence in 
Newfoundland and Labrador (NL). Implantable Cardioverter Defibrillator (ICD) treatment has 
been found to be lifesaving in this population, however ICD treatment is not without side effects 
which can include mental health concerns. Partners of patients with a disease, while genetically 
unaffected, have the potential to be impacted by the disease. Qualitative data and anecdotal 
knowledge within the ARVC research team indicated that there may be serious mental health 
concerns in all TMEM43 family members including partners, negative relatives not just the ICD 
patients themselves. This study aimed to quantitatively study the prevalence of anxiety, 
depression, and post-traumatic stress (PTSD) symptoms in the partners of ICD patients. 
Methods: Partners of ICD patients as treatment for ARVC caused by a TMEM43 p.S358l variant 
were recruited. Participants completed the Zung Self Rating Anxiety Scale (SAS), Patient Health 
Questionnaire-9 (PHQ-9), and the PTSD Checklist for Civilians (PCL-C). Prevalences of 
anxiety, depression, and PTSD symptoms were described in the partners and compared with 
scores of ICD patients, negative relatives and the general population. Associations between 
partners scores and demographic and clinical data was also analyzed.  
Results: Twenty-six partners participated that ranged in age from 19-69 and 54% were female. 
Clinically significant scores for anxiety, depression, and PTSD were found in 25%, 12%, and 
65% of partners respectively. Scale score were significantly related to one another(p=0.001-
p=0.016). Partners PCL-C scores were significantly positively associated with their partner with 
the ICD’s PCL-C score(r(24)=0.593, p=0.002), number of appropriate shocks experienced by 
their partner with the ICD(rS(24)=0.564, p=0.005), and if the partner with the ICD went on to 
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have a heart transplant(t(24)=3.497,p=0.002). Partners were found to have significantly 
higher(p=0.037) scores for PCL-C than negative relatives. Compared to the general population 
partners had significantly higher rates of anxiety(p<0.001) and PTSD(p<0.001). 
Conclusion: The partners of ICD patients as treatment for ARVC caused by a TMEM43 p.S358l 
variant are experiencing significant mental health sequale. Additional mental health supports 
within this population are needed. Further research to better understand these symptoms and the 






















Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a heart disease that can 
result in death. In Newfoundland and Labrador (NL) there is a particularly deadly type ARVC. 
Most individuals with this disease are treated using an Implantable Cardioverter Defibrillator 
(ICD). The ICD treatment is not a cure and can have lifelong physical and mental side effects. 
Preliminary research indicated that all family members, including partners, could be at risk of 
being impacted by the disease and the treatment. Symptoms of anxiety, depression and post-
traumatic stress disorder (PTSD) were measured in the partners of ICD patients in the ARVC 
population of NL. Significantly high levels of PTSD were found in partners. Scores of each 
survey were significantly associated with one another. PTSD scores of the partners were 
significantly associated with the severity of the disease of the partner with the ICD. The partners 
were found to have higher rates of PTSD and anxiety than the general population. This study 
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CHAPTER 1. INTRODUCTION 
 
When settlers arrived in North America in the 1400’s they brought with them, among 
other things, the nuclear family structure and foreign deoxyribonucleic acid (DNA).1 A nuclear 
family is a unit that comprises two adults in a relationship and their children. Historically the 
definition was limited to heterosexual couples but has since been expanded to include same sex 
couples.2 While many aspects of Canadian society and culture have evolved over the past 600 
years, the nuclear family remains the predominant household type. Couples, with or without 
children, accounted for 52.3% of Canadian households in 2016.3 In contrast to the unchanging 
family structure, our knowledge of genetics has evolved rapidly since the settlers’ arrival; from 
Mendel and his peas in 1865, to the recognition of Rosalind Franklin’s work which provided the 
crucial piece of evidence leading to the discovery of the double helix by Watson and Crick in 
1953, to the human genome project in the 1990’s, to today’s commercially available DNA 
ancestry kits and the ease with which human DNA can be sequenced.4 Included in these 
advancements, and likely of greatest medical impact, is the discovery of causative genes for 
many hereditary conditions.5 This has allowed for predictive genetic testing, which can identify 
disease carriers before symptoms appear and may improve treatment of the condition.6  
While not biologically affected by disease, a partner living with someone with a disease 
is in a very unique position, with a potential for impact unrelated directly to personal disease 
status. Unlike multi-generational households where the burden of family life, including care-
giving is shared amongst multiple family members, the nuclear structure is largely independent 
with the couple’s main support being one another. The impacts, both mental and physical, of 
having a partner with a disease have been studied in wide array of diseases. A meta-analysis of 
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the spouses of cancer patients found partners to have the same levels of anxiety as their diseased 
partners which were significantly higher than healthy controls.7 Similarly, equally high levels of 
emotional distress were found in both individuals with Huntington’s disease and their partners.8 
In a study on patients with epilepsy, higher rates of Post-Traumatic Stress Disorder (PTSD) in 
their partners was associated with the severity of the seizures.9 A study on an array of diseases 
and disabilities found caregiving partners to be at a significantly increased risk for stroke and 
coronary heart disease.10 Research on the partners of Alzheimer’s patients found the partners to 
have declining immune function that is thought to be due to accelerated telomere erosion.11 
Research into partners’ experiences, which is the focus of this thesis, is important not only to 
improve partners’ outcomes, but also the individual with the disease. Having a supportive and 





The function of the heart is to pump blood throughout the body. The heart consists 
mainly of muscle tissue (myocardium), divided into four chambers, the left and right atria (upper 
chambers) and the left and right ventricles (lower chambers). The right atrium receives oxygen 
poor blood from the body and pumps it into the right ventricle. From there, the blood is pumped 
into the lungs and oxygenated. The oxygen rich blood is received by the left atrium and pumped 
to the left ventricle and subsequently back into the body. Functioning of the heart can be 
impacted by a number of factors. Some examples include plaque buildup from Coronary Artery 
Disease (CAD) that reduces the amount of blood entering the heart or valve malfunctions that 
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impact the amount of blood entering the atria or ventricles.  Diseases specific to the functioning 
of the ventricles are known as Cardiomyopathies. These diseases are defined by Maron et al. as 
“a heterogeneous group of diseases of the myocardium associated with mechanical and/or 
electrical dysfunction that usually (but not invariably) exhibit inappropriate ventricular 
hypertrophy or dilatation and are due to a variety of causes that frequently are genetic. 
Cardiomyopathies either are confined to the heart or are part of generalized systemic disorders, 
often leading to cardiovascular death or progressive heart failure–related disability.”14 These 
abnormalities make it harder for the ventricular myocardium to pump blood from the heart to the 
rest of the body. The cardiomyopathies are classified based on their morphologies into five types, 
Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Restrictive 




The human body is an intricate composition of over 37 trillion cells, each performing a 
specific role, with the combined effect of creating a functional human being.15 Each cell contains 
DNA which instructs the cell in its specific role. In some cases, this DNA is mutated, which can 
affect the cells ability to function and may lead to disease. Diseases caused by genetics can be 
hereditary, meaning inherited from a parent’s DNA, or de novo, where a spontaneous mutation 
has occurred. The disease at the heart of this project is ARVC. ARVC is part of the larger group 
of heart diseases known as cardiomyopathies.  
ARVC is a rare genetic disease estimated to affect one in every 1000-5000 people.16 Its 
cause is heterogeneous with over 13 associated genes and disease-causing variants within those 
genes identified to date.17,18 The mechanism of this disease is not fully understood. It typically 
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follows an autosomal dominant inheritance pattern, where each child of an affected parent has a 
50% chance of getting the gene variant. Whether the person with the variant develops the disease 
depends on the penetrance. Penetrance is the proportion of individuals with the genetic variant 
who exhibit traits of the disease. 
Of those affected by ARVC, approximately half have variants in genes that encode for 
cardiac desmosomes. Desmosomes are intracellular junctions that provide adhesion between 
cells. It is hypothesized that the myocardial cells detach from one another due to the abnormal 
desmosomes; these damaged cells are then replaced by fibrofatty tissue.16 As more of the 
myocardium is replaced by the tissue, the heart wall begins to stretch out, preventing the heat 
from effectively pumping blood. Similar to the genotype, the disease phenotype is highly 
variable. Symptomology can range from asymptomatic, to arrhythmias, to sudden cardiac death 
(SCD).18 Symptomatic patients generally present with ventricular arrhythmias which can 
manifest as palpitations, presyncope, or syncope.  
ARVC is a progressive disease and once symptoms appear, they will continue to worsen. 
Without treatment ARVC can lead to SCD or heart failure. Despite the progressive nature of the 
disease, the first symptom can sometimes be SCD. The variability of the disease is also observed 
by the influence of sex, with men being at a greater risk of fast ventricular tachycardia (VT).16  
Diagnosis of ARVC can be challenging due to phenotypic variability. In 1994 an 
International Task Force created criteria for diagnosis that took structural, histological, 
electrocardiographic, arrhythmic, and familial features in to account to address the variability.19 
The criteria are divided into two categories, major and minor. A diagnosis of ARVC could be 
made if the patient had either two major criteria, or one major plus two minor criteria, or four 
minor criteria. These criteria were informed mainly by ARVC patients that were symptomatic or 
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suffered SCD, which means the criteria may lack sensitivity for asymptomatic or familial 
cases.2020  
In 2002, a Hamid et al. found that 11% of probable ARVC diagnoses were being missed 
by the International Task Force criteria. Hence the criteria were broadened to be more inclusive 
of the asymptomatic to mild end of the disease spectrum.21 A further study was done in 2010 to 
reflect advances in technology and knowledge of the disease.20 Computer programs and 2D 
Magnetic Resonance Imaging (MRI) are able to give detailed readings and pictures of 
abnormalities of the heart and its function. This study led to a further, and most recent, 
amendment of the criteria which increased the diagnostic sensitivity without losing specificity.20 
See Appendix 1 for task force criteria.  
Once a diagnosis is made, cascade screening is used to identify at risk family members. 
Cascade screening can be complex even when the original diagnosed patient, the proband, is 
willing to cooperate. Family histories are taken, pedigrees created, and family members near and 
far are contacted. Then there are appointments with doctors, nurses, and genetic counsellors. It is 
truly a family affair. This process can be further complicated by family dynamics.  
1.2.1 TREATMENT 
 
There is currently no cure for ARVC. However, both pharmacological and mechanical 
treatments are available to treat the disease and attempt to slow the progression. A 
pharmacological approach to slowing the heart rate and hopefully preventing arrhythmias is 
usually the first course of treatment. One of the drug classes used for this purpose are beta-
adrenoceptor antagonists, more commonly known as beta blockers. Beta blockers work by 
slowing the heart rate and conduction through the atrioventricular node, which can suppress 
dysrhythmias.22 In addition to their ability to reduce arrhythmias, beta blockers can have 
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negative side effects including dizziness, fatigue, trouble breathing, depression, weight gain, 
nightmares, cold hands and feet, and decreased sexual activity. The other type of drugs used to 
treat ARVC are antiarrhythmic drugs (class I and III).16 Antiarrhythmic drugs work by altering 
membrane ion conductivity which affects cardiac action potential. Class I are sodium-channel 
blockers that reduce the rate of depolarization and class III are potassium-channel blockers that 
reduce the rate of repolarization. Both function to slow conduction between cardiac cells, which 
can suppress arrhythmias. Anti-arrhythmic drugs, however, come with an array of potential side 
effects including, dizziness, gastrointestinal problems, and changes in heartbeat.  
If drugs alone are not enough to prevent arrhythmias, another method of treatment is an 
Implantable Cardioverter Defibrillator (ICD).16 An ICD is a device that is implanted under the 
skin on the chest and lead wires are fed into the heart. The device is about the size of small box 
of matches and once implanted the outline can usually be seen under the skin. Its purpose is to 
detect abnormal heart rhythms and correct them. If an abnormal rhythm is detected, the device 
will attempt to pace the heart back to normal. If this does not work, it will deliver an electric 
shock to correct the sustained VT/ventricular fibrillation (VF) to return the heart to sinus rhythm 
and prevent sudden death.23 The heart rate required to trigger the device is individualized to each 
patient. Some ICD patients can feel their heart racing and know a shock is coming, while others 
have no warning at all. The VT or VF may impact the heart’s ability to perfuse blood to the point 
the patient does not receive enough oxygen to their brain and they may lose consciousness before 
the shock. When the device fires, the shock has considerable force, sometimes described as being 
kicked in the chest by a horse.  
Patients with an ICD are followed up regularly by a cardiology team including a 
cardiologist and specialized nurses. At these appointments, the device history is reviewed for any 
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abnormal heart rhythms or shocks, either appropriate or inappropriate. The ICD device is battery 
powered and a replacement battery and accompanying surgery are needed approximately every 
ten years.  
Possible complications from an ICD include both physical and psychological impacts. 
Physical complications include infection of the incision or along the device. Another is lead 
fracture, where the wire going from the device into the heart breaks and may require another 
surgery to correct.24 The other major physical complication is the delivery of inappropriate 
shocks. Inappropriate shocks occur when the patient has a normal fast heart that is outside the 
prescribed threshold and the device interprets this as an abnormal rhythm or less often, when the 
device malfunctions and fires outside of the prescribed heart rate threshold.25 Psychological 
complications include an increased risk of negative mental health impacts. A systematic review 
found a 20% prevalence rate for depressive and anxiety disorders in patients with an ICD and a 
separate study found a similar prevalence rate of PTSD.26,27 Due to the risk of complications of 
the ICD treatment, it is reserved for patients at a high risk of SCD.28  
ICD treatment can be indicated for primary or secondary prevention. Primary prevention 
is when the device is placed in a patient with no history of SCD or VT/VF and secondary 
prevention is when an ICD is placed after a patient has shown symptoms, such as sustained VT 
or an aborted SCD. Using an ICD for secondary prevention is more common and utilized for 
conditions such as ischemic heart disease and genetic cardiomyopathies.29 Guidelines for ICDs 
as secondary prevention for ARVC are well established, with the latest being published in 
2015.28 Primary prevention guidelines are less established and have usually been left to 
physician’s discretion.  
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ICD placement is an invasive treatment requiring surgery, lifelong device dependence, 
and risk of complications; however, it is a lifesaving treatment. Studies estimate a 20-30% 
reduction in mortality in patients that received an ICD as treatment for ARVC.30  
 1.3 ARVC IN NEWFOUNDLAND AND LABRADOR (NL) 
 
ARVC has been identified and studied across the globe with one of the most studied 
populations being here in NL.31 NL was populated by a small number of European settlers and 
Indigenous peoples. The people were historically isolated by the remote geography of the 
province and this resulted in a founder population with reduced heterogeneity.32 
Newfoundlanders and Labradorians also have a strong connection to their families and their 
home. This connection means many people in the province can trace their lineage back for 
generations and across to distant cousins. This unique NL population has aided in the study of 
several monogenic diseases including a subtype of ARVC caused by a p.S358L variant in the 
Transmembrane Protein 43(TMEM43) gene.33,34  
Until the late 1900’s certain families across NL suffered from a mysterious condition 
where the men in the family would often drop dead at a young age without any prior warning. In 
the late 1970’s, a diagnosis of ARVC was made in one of these families.35 Over the next few 
decades, extensive research was conducted on the families with ARVC and a history of SCD 
from which families were ascertained and pedigrees mapped. This research also led to the 
creation of a database of all individuals born at a priori 50% risk for ARVC. Due to the 
autosomal dominant mode of transmission, all children of an affected parent are at 50% risk of 
inheriting the disease-causing variant.  
Genetic study of the individuals in this database led to the 2008 discovery of the 
causative gene for this particular type of ARVC as a p.S368L variant in TMEM43.34 This 
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variant is thought to have originated in Europe from a single founder approximately 1400 years 
ago.36 The TMEM43 gene encodes for a highly conserved 400 amino acid protein that contains a 
transactivation domain, four transmembrane domains, and sites for phosphorylation, O-
glycosylation and sumoylation.37,34 The variant p.S358L indicates that in the protein codon 
sequence a serine has been replaced by a lysine. See Figure 1.1 for illustration of TMEM43 
protein with p.S358L mutation. 
 
Figure 1.1 Predicted Topography of the TMEM43 Protein Used with Permission1 
 
1 Reprinted from, American Journal of Human Genetics, 82/4, Merner ND, Hodgkinson KA, Haywood AFM, et al., 
Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Is a Fully Penetrant, Lethal Arrhythmic Disorder 
Caused by a Missense Mutation in the TMEM43 Gene, 809-821, 2008, with permission from Elsevier 
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 To date 27 families with the p.S358L variant have been identified in Newfoundland, the 
largest of which spans ten generations and is comprised of over 1500 members.  Unlike other 
forms of ARVC, the p.S358L variant is fully penetrant and everyone with the variant will at 
some point in their lives show evidence of having the disease.34 Although all affected will have 
some sign they have the disease, this disease has a high degree of variability of expression.33  
ARVC caused by the p.S358L variant in the TMEM43 gene is a particularly lethal 
subtype where SCD is often the first symptom. Manifestation of the disease is sex influenced 
favouring females. Left untreated, the median age of death for males is 40 and females 67.33 A 
study on the TMEM43 population in 2016 compared the survival curves of ARVC patients 
treated with ICDs and controls. The study showed that appropriate firings of the ICD for 
sustained VF/VT were considered an aborted death where the patient would have died if left 
untreated.38 These results, coupled with the first symptom often being SCD, suggested an ICD 
for primary prevention was indicated. Individuals found to have the TMEM43 p.S358L variant 
are recommended for prophylactic ICD implantation post puberty for males and ≥30 years for 
females. However, some females may be given an ICD earlier if they have clear clinical signs, or 
if the female patient is psychologically compromised by not having an ICD.38 This treatment 
course means ARVC families may have many members with ICDs. Often these individuals are 
being implanted young and hence are living with the device for the majority of their lives.  
In Newfoundland all ICD treatment and management takes place at the cardiac clinic 
within the Health Science Centre hospital in St. John’s. ICD patients attend the cardiac clinic 
twice a year where they meet with specialized nurses, doctors, and technicians who monitor the 
functionality of the device. It is important to note there is currently no systematic provision of 
mental health care for ICD patients or their families.  
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1.4 DISEASE IMPACT ON UNAFFECTED PARTNERS 
 
As previously discussed, ICD treatment is life altering and comes with serious risk of 
complications. Most individuals with an ICD do not experience the disease or subsequent ICD 
treatment in isolation. The majority have families and partners who, while unaffected genetically 
by the disease, are affected in other ways. A study by Etchegary and the SCD team in 2017 
looked at the psychological impact of having an ICD on both variant positive and negative 
members in the TMEM43 families.39 A range of impacts were discovered affecting emotional 
and psychological health, family dynamics, intimate relationships, and recreational activities. 
The results showed negative mental health effects not only in the variant positive ICD recipients, 
but also in the variant negative relatives and spouses. This qualitative data, along with anecdotes 
from clinicians and TMEM43 families, highlighted the need for further research and quantitative 
data on the mental health sequale of this population. 
To address this gap in the literature, a three-armed survey study was planned. Across all 
three arms, quantitative measurement of psychological impacts, specifically anxiety, depression, 
and PTSD within the TMEM43 population was undertaken. The study population included three 
cohorts, variant positive ICD patients, their variant negative partners, and negative first-degree 







CHAPTER 2. LITERATURE REVIEW 
 
A search of the literature was performed using PubMed, The Cochrane Library and 
Memorial University of Newfoundland (MUN) library.  MeSH terms “Implantable cardioverter 
defibrillator” and “spouse” were used in PubMed and returned 23 results, seven of which were 
relevant to this study. A separate search using MeSH terms “Implantable cardioverter 
defibrillator” and “partner” yielded 267 results, eight that were relevant to this study of which 
five did not overlap with the previous search. Additional searches were performed using MeSH 
terms “Implantable cardioverter defibrillator” and “spouse” with “anxiety”, “depression” and 
“PTSD” which yielded no new results. This process was repeated for MeSH terms “Implantable 
cardioverter defibrillator” and “partner” with “anxiety”, “depression” and “PTSD” also yielded 
no new results. A search of The Cochrane Library yielded no results. A search of the MUN 
library using all above searches and terms yielded one new result. A final search using MeSH 
terms “arrhythmogenic right ventricular cardiomyopathy” and combinations of “partner”, 
“spouse”, “anxiety”, “depression”, and “PTSD” yielded no new results. 
 
2.1 PARTNERS OF ICD PATIENTS AND DEPRESSION AND ANXIETY 
  
Dougherty et al. (1995) explored the psychological reactions and family adjustment in 
ICD patients and their partners.40 The ICD patients had received this treatment post cardiac arrest 
from cardiac fibrillation. The cohort was divided between ICD patients who received shocks and 
their partners, and those who received no shocks. This was a longitudinal study following 15 
ICD patients and 15 partners with data collection at hospital discharge, six-months, and one-year. 
Psychological reactions, including anxiety and depression were measured using the Profile of 
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Mood States Questionnaire (POMS) and the State-Trait Anxiety Inventory(STAI). Anxiety 
levels of the partners was found to be higher than that of the ICD patients. Of the partners, those 
with partners who had shocks, had higher levels of anxiety than those of partners who had no 
shocks. Despite the small sample, results clearly demonstrated negative mental health impacts of 
ICD therapy on partners.  
  In 2004, Pedersen et al. described the prevalence of anxiety and depression 
symptoms in ICD patients and their partners and explored the role of personality factors and 
social support as determinants of distress.41 This was a cross sectional study of 182 ICD patients 
and 144 partners in the Netherlands. The authors did not indicate the reason for the patient 
receiving an ICD. Anxiety and depression were measured using the Hospital Anxiety and 
Depression Scale (HADS). Results revealed that symptoms of anxiety were significantly more 
prevalent in partners (42%) than ICD patients (31%) and depressive symptoms were equally 
prevalent between the groups (28%-29%). Male partners had significantly more anxiety 
symptoms than female partners, with no difference in depression symptoms between sexes. 
Partners using psychotropic medication had a higher prevalence of anxiety and depression 
symptoms than partners using no medication. The study also found that partners with Type D 
personality were more likely to suffer from symptoms of anxiety and depression. Type D 
personality, distressed personality, is one where individuals experience negative affectivity and 
social inhibition.42  
 A study by Sowell at al (2007) in Florida, USA looked at anxiety and marital adjustment 
in patients with an ICD and their partners.43 This cross-sectional study consisted of 40 patients 
with ICDs as treatment for ischemic cardiomyopathies and 22 partners. Data collection happened 
at clinic appointments using the following scales: Multidimensional Fear of Death Scale 
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(MFODS) for death anxiety, Florida Shock Anxiety Survey (FSAS) for shock anxiety, Revised 
STAI for general anxiety, and Dyadic Adjustment Scale (DAS) for marital adjustment and 
quality. The results found no difference between ICD patients and partners for death or general 
anxiety, but partners had significantly higher shock anxiety. 
 In 2009, Pedersen et al. published another study examining the prevalence of anxiety and 
depression symptoms on ICD patients and their partners in the Netherlands.44 This longitudinal 
study had 392 participants total, 196 ICD patients and 196 spouses; again, it was not noted why 
ICD implantation was indicated. Patients and partners were given the HADS scale pre and six 
months post implantation. They were also assessed for Type D personality. The results showed 
significantly higher prevalence of anxiety symptoms in partners as compared to patients both 
pre- and post-implantation. Anxiety symptoms in both groups had a significant reduction at post 
implantation compared to pre. They also found no difference in partner’s anxiety symptoms 
when stratified by sex. No statistically significant differences were found for depression 
symptoms between patients and partners. Higher levels of anxiety and depression symptoms in 
partners were associated with the ICD patient receiving shocks when the ICD was for secondary, 
not primary prevention.  
 Also in 2009, Dougherty et al. reported on partners’ mental and physical health after ICD 
implantation in their spouses as treatment for sudden cardiac arrest.45 This prospective, 
longitudinal study collected data from partners at hospital discharge, one-, three-, six-, and 12-
months post implantation. 100 partners were recruited from across the Pacific Northwest and 
completed the Short Form Health Survey (SF-12PCS) for physical health, STAI for state anxiety, 
and Centre for Epidemiologic Studies Depression (CES-D) for depressive symptomology. The 
study found that partners’ physical health scores declined significantly from discharge to both 
 15 
three- and 12-months. Anxiety levels in partners at hospital discharge were high (39.2112.81) 
where a score of 40 indicates severe anxiety and level remained elevated, though significantly 
reduced, at 12-month follow up (35.612.47). Levels of depression in partners was not found to 
be elevated at any of the measurement points, but did reduce significantly from the baseline at 
each point. 
A study from the United Kingdom (UK) was published by Redhead in 2010 examining 
psychopathology in patients with ICDs as secondary prevention post infarction and their 
spouses.46 This cross-sectional study recruited participants from hospitals and had 100 ICD 
patients, 41 spouses, 284 cardiac control cases, and 89 spouse control cases. Anxiety and 
depression were measured using HADS and quality of life measured using the Medical 
Outcomes Study Short-Form 36 (MOF SF-36). Results found high levels of anxiety (47%) and 
depression (14%) in ICD spouses compared to the rate of anxiety (4%) and depression (1.2%) in 
the UK general population.  
 In 2011 a systematic review was published by Palacios-Ceña et al. on qualitative research 
examining patients’, partners’, and family members’ experiences with an ICD.47 This review 
covered research from 1999-2009 and included 22 papers. Findings on partner experience 
included changes in life view where partners searched for deeper meaning of the experience. 
Various studies showed that immediately following implantation, patients and partners 
experienced a period of physical, psychological and emotional adaptation with normal cognitive 
function returning after six months. Sexual intimacy was a concern among patients and partners 
focusing on worrying if sexual activity would trigger arrhythmias and if the intimate relationship 
would return to normal. 
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 Van Den Broek at al published a study in 2013 looking at anxiety and depression in ICD 
patients and their partners.48 This was a longitudinal study where 343 patients and partners were 
recruited from hospitals where data collection happened at implantation and two-, 12-, and 18-
months post-surgery. Type D Scale (DS14) was used to measure Type D personality, STAI to 
measure state anxiety and the Beck Depression Inventory (BDI) for depressive symptoms. The 
study found partners had significantly higher levels of anxiety than patients at implantation but 
no significant differences at follow up points. Partners had significantly lower levels of 
depression at all measurement points except at two-months post implantation. Partners’ and 
patients’ anxiety and depression levels were significantly positively correlated at all 
measurement points. Partner anxiety and depression was associated with partner Type D 
personality.  
 A 2015 study by Brouwers et al. examined the Health Status and psychological distress 
of partners of patients with a Left Ventricular Assist Device (LVAD) compared to partners of 
patients with an ICD.49 This was an observational study of 33 partners of LVAD patients and 
414 partners of ICD patients from hospitals in the Netherlands and Canada. Data collection 
happened one-day prior to implantation and three- and six-months post-surgery. Health status 
was measured using SF-12, anxiety and depression measured by HADS, and type D personality 
using DS14.They found the prevalence of anxiety among partners of ICD patients to be highest 
pre-implantation (43%) that declined over time to be the lowest (31%) at six-month follow up. 
The prevalence of depression in partners (21-22%) was stable throughout baseline and follow up 
points.  
 Dougherty et al. (2016) that compared patient and partner quality of life and physical 
health outcomes after ICD treatment.50 Patients received an ICD as secondary prevention 
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following SCA or serious VA. Forty-two ICD patients and 42 partners participated in the 
longitudinal study where data was collected at ICD implantation, then one-, three-, six-, and 12-
months post-surgery. Mental health was assessed using Short Form Health Survey for mental 
health (SF-12 MCS), depression with CES-D, and state anxiety using STAI. The study found at 
baseline 48% of partners had elevated anxiety scores and 29% had elevated depression scores. 
There were no significant changes to scores across the measurement periods. Partners had 
significantly higher anxiety than patients, but there was no difference for depression.  
A 2018 study from the Netherlands by Rottman et al. looked at psychological distress in 
ICD patients and their partners.51 This longitudinal study included 286 ICD patients and their 
partners and followed them from one-day pre implant and ten-day, three-, six-, and 12-months 
post-surgery. Two thirds of patients had ICDs as primary prevention. The HADS was used to 
measure symptoms of anxiety and depression. The study found partners had significantly more 
anxiety than patients and no significant differences were found for depression. Both anxiety and 
depression scores in partners improved significantly over time. Having a partner who received 
ICD shocks was significantly associated with less improvement over time for symptoms of both 
anxiety and depression.  
 From the scant literature available about the mental health of partners of patients with 
ICDs, certain trends are notable. Symptoms of anxiety in partners tends to be higher than ICD 
patients, particularly immediately prior to and following implantation. Depression symptoms do 
not differ significantly between partners and ICD patients regardless of time from implantation. 
Where prevalence is measured, significant levels of anxiety and depression are found in 42-47% 
and 14-28% of partners respectively. Additionally, being a partner of an ICD patient who has 
received shocks is associated with higher levels of anxiety. While some research found that 
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partners with Type D personality profile had higher levels of anxiety than those without this 
profile, in the main, partners generally had higher levels of anxiety than their partners with an 
ICD 
2.2 PARTNERS OF ICD PATIENTS AND PTSD 
 
A noticeable gap in the literature is in the study of partner post-traumatic stress. There are 
currently no available studies exploring the prevalence of PTSD symptoms in partners of ICD 
patients.  
2.3 PARTNERS OF ICD PATIENTS WITH ARVC 
 
Only one study was found that explored the mental health of partners of ICD patients as 
treatment for ARVC. This study by Etchegary et al. out of Newfoundland, Canada was a 
qualitative interview study that included nine patients with an ICD as treatment for ARVC 
caused by a TMEM43 p.S358l variant, eight variant negative family members, and four 
spouses.39
 
Data analysis revealed four major themes. The first was acceptance and gratitude, 
where spouses acknowledged the lifesaving effect of the ICD. The second was grudging 
acceptance where despite the known benefits, acceptance of the ICD was somewhat grudging 
and took time. Third was the psychological impact which was further divided into emotional and 
psychological wellbeing, functioning of the broader family unit, and relationships. In this theme, 
spouses acknowledged feelings of anxiety, depression, fear, guilt, and challenges with 
interpersonal relationships. The final theme was practical concerns, where spouses’ lives were 
tangibly and practically affected by the ICD patients’ loss of a licence and availability of medical 
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care in the province (limiting recreational activities such as travel). This small pilot study 
revealed a host of negative mental health impacts on both ICD patients, but also their spouses.  
2.4 PREVALENCE OF ANXIETY, DEPRESSION, AND PTSD IN GENERAL POPULATION 
 
Data on the prevalence of mental health issues was not available for the Newfoundland 
Population. The next closest comparable population is that of Canada. The most common anxiety 
disorder, generalized anxiety disorder has a 12-month and lifetime prevalence of 2.6% and 8.7% 
respectively.52 The 12-month and lifetime prevalence of major depressive disorder is 11.3% and 




 In summary there is a paucity of literature available on the mental health impacts on 
partners of ICD patients and even less on ARCV populations specifically. What is available 
shows that ICD patients are not carrying the burden alone; the impact of this treatment is also felt 
by partners who have significant mental health concerns. It is clear that more research is 









CHAPTER 3. METHODS 
 
This study occurred over two phases. Initially, a patient engagement meeting was held, 
which included a small number of ICD patients, their partners, and negative relatives. This 
meeting allowed the team and affected families to discuss the project and ensure the project’s 
focus aligned with patient priorities. Information from this meeting informed the creation of the 
study protocol. Phase two of the project included a cross sectional survey study measuring 
anxiety, depression and post-traumatic stress in partners of ICD patients affected by ARCV.  
 
3.1 PURPOSE OF STUDY 
The purpose of this study is to provide initial data on mental health sequale in partners of 
individuals with an ICD as treatment for ARVC caused by a TMEM43 p.S358L variant and more 
broadly contribute to a better care experience for these families; to help raise awareness of 
mental health issues in these families, to provide information for health system decision makers 
and providers who work with these families that ultimately leads to an inclusion of mental health 
care for these families. 
3.1.1 RESEARCH QUESTION 
What is the prevalence of symptoms of anxiety, depression, and post-traumatic stress disorder in 
adult partners of ICD patients as treatment for ARVC caused by a TMEM43 p.S358L variant? 





1. Determine the prevalence of anxiety, depression, and posttraumatic stress symptoms in 
the partners of ICD patients. 
2. Determine whether the severity of psychiatric symptoms correlate with severity of 
disease in their partner and/or their family. 
3. Compare the prevalence of psychiatric symptoms in partners of ICD patients with general 
population levels. 
4. Compare the prevalence of psychiatric symptoms between the different family groups 
(ICD recipients, unaffected family members, and partners of ICD recipients). 
5. Obtain data that might inform the provision and type of health care in this patient cohort 














3.2 STUDY POPULATION 
 
Figure 3.1 Sample Pedigree of the TMEM43 p.S358L Population with Unaffected Partners 
Highlighted2 
 
Of the twenty seven families with the p.S358L variant in the TMEM43 gene in NL, the first 15 
are the best ascertained, have a long standing relationship with the genetics/cardiac team at 
MUN, and have previously consented to be part of ongoing genetic studies (Health Research 
Ethics Board(HREB); study #:00-176). To attain manageable participant numbers for this pilot 
study, the first 8 of the 15 families were primarily ascertained for a study invitation. The 
expansive dataset (HREB; 00-176) and pedigrees were accessed with permission from the data 
 
2 Used with permission From Dr. Kathleen Hodgkinson. 
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custodian Dr. Hodgkinson and the project was approved by the HREB (study #: 2017-071). See 
Figure 3.1 for sample pedigree highlighting unaffected partners. From searching this data, 106 
ICD patients, 148 variant negative first-degree relatives, and 59 partners were identified. The 
responsibility for accessing, collecting and analysing each group formed the basis of three 
different M.Sc. projects headed by three different students. ICD patients were studied by Dr. 
Magda Orzylowski, partners of ICD patients by Ms. Mary Walsh (the author of this thesis), and 




From the literature review it was clear there was no standard of evaluating the mental 
health of partners of ICD patients. While the majority of studies did measure anxiety and 
depression, the methods were varied. Some focused on anxiety and depression within the 
hospital setting, and others measured types of anxiety, including shock anxiety separately. 
Additionally, there were no studies to reference that examined PTSD symptoms in partners. 
Within the larger field of cardiac research there are many mental health scales utilized. For 
anxiety and depression some examples are: HADS, SF-12MCS, and BDI.55,56,57,58 For PTSD: 
Post Traumatic Diagnostic Scale (PTDS) and PTSD Checklist Specific (PCL-S).59,60  
 The purpose of this study was to gather quantitative data on the prevalence of symptoms 
of anxiety, depression, and PTSD. The scales chosen needed to be brief and easy to understand 
since they would be self-rated. They also needed to be validated and reliable within cardiac 
populations. While a diagnosis of anxiety, depression, or PTSD would not be possible without 
the involvement of a qualified mental health professional, the research team wanted scales that 
could screen for these conditions and reliably identify symptoms of these disorders.  
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Ultimately the instruments chosen were the Zung Self Rating Anxiety Scale (SAS), the Patient 
Health Questionnaire-9(PHQ-9), and the PTSD Checklist for Civilians (PCL-C) all three of 
which are validated and used widely across multiple health populaitons.61,62,63  
3.3.1 ANXIETY 
 
The SAS is a 20-item self-rated measure of anxiety symptoms with a four-point response 
scale: one-a little of the time, two-some of the time, three-good part of the time, and four-most of 
the time. The scale focuses on the respondent’s physical manifestations of and feelings of 
anxiety.  The possible range of scores is 20-80. This score is then converted to an anxiety index 
with scores ranging from 25-100. This index score corresponds with severity of anxiety 
symptoms: <45 points = normal range, 45-59 points = minimal to moderate anxiety, 60-74 points 
= marked to severe anxiety, and ≥75 points = most extreme anxiety.61 This scale has been 
validated as a screening tool for anxiety and has been shown to be a significant predictor of an 
anxiety diagnosis.64 A cut off threshold of 45 and above was chosen for this study. Participants 
scoring above this threshold were considered to be positive for anxiety. See Appendix 2 for a 
copy of the SAS. 
3.3.2 DEPRESSION 
 
The PHQ-9 is a nine item self-rated measure of depression symptoms with a four-point 
response scale: zero-not at all, one-several days, two-more than half the days, three-nearly every 
day. The questionnaire focuses on the respondent’s energy levels and ability to function in 
everyday life. The possible range of scores is zero to 27. This score corresponds with the level of 
depression severity: zero to four = minimal, five to nine = mild, 10-14 = moderate, 15-19 = 
moderately severe, 20-27 = severe. This scale is a reliable and valid measure of depression 
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severity.62 A score of ≥ten has a 78% sensitivity and 96% specificity for any depression 
diagnosis.65 A score of ten or greater was chosen as the cut-off threshold for this study and 
participants above this threshold were considered positive for depression. See Appendix 3 for a 
copy of the PHQ-9. 
3.3.3 PTSD 
 
The PCL-C is a 17-item self-rated measure of PTSD symptoms with a five-point response scale: 
one-not at all, two-a little bit, three-moderately, four-quite a bit, and five-extremely. The 
checklist focuses on the respondent’s ability to cope with everyday life and physiological 
disturbances. There are three versions of this scale, a military, a specific and a civilian. The 
civilian version was used in this study. This scale is a valid and reliable measure of PTSD 
symptoms.63 The interpretation and scoring of this scale was not as straightforward as the two 
previous scales. When choosing a threshold cut-off, the target setting and population had to be 
considered as per the National Centre for PTSD. The rate of PTSD within this specific 
population was not known. Prevalence estimates of PTSD in patients with ICDs as treatment for 
ARVC vary from 21-31%.66,67,68,69 Clinical experience of the research team, coupled with pilot 
qualitative data and discussion during the patient engagement session, suggested the prevalence 
could likely be just as high within the partner population.39 Therefore, a cut-off point of 36 and 
above was chosen, which corresponds to a PTSD prevalence 16-39. Participants scoring 36 and 
above were considered PTSD positive. A score of 44 or above was chosen to a high score for 






3.4.1 PATIENT MEETING 
Members of two families affected by ARVC were contacted by a clinical professional in 
their circle of genetics care (Dr. Hodgkinson) and invited to attend the patient engagement 
session. The families contacted were chosen through purposeful sampling: they have a long-
standing relationship with the research team and a long history with the disease. Experiences 
within families also varied in terms of numbers of affected family members, SCD in the family, 
family dynamics and relationships, and numbers of at-risk relatives. Collectively, participants in 
the patient engagement session represented varied experiences with ARVC and ICD therapy.  
3.4.2 QUANTITATIVE 
Study packages were created that contained a cover letter/consent form, the three scales, 
and contact information for mental health and study support. These packages were linked to the 
participant by their research number from the longstanding previous research project (HREB 00-
176). This allowed the packages to be de-identified and could only be connected to the original 
participant through the dataset from the long standing SCD cardiac research group. This research 
number does not exist anywhere else in the patient record.  Copies of the cover letter/consent 
form and support contact information can be accessed in Appendices 5 and 6 respectively. The 
packages were delivered in the following ways: 
1. ICD patients are seen every six to twelve months at the cardiac clinic for follow up on 
their condition and device. They may be accompanied by their partner. At the 
appointment, a member of their health care team asked each ICD patient (and partner 
if present) if they were willing to speak to a member of the research team. If 
agreeable, the project was then explained by a team member. If the ICD patient (and 
partner) consented to participate, they were given the option of completing the 
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questionnaires in a private room or taking them home and returning by mail. This 
method of recruitment began in September of 2017 and ceased in September of 2018. 
2. Partners of ICD patients who had not been successfully contacted through the clinic 
were contacted by Dr. Hodgkinson by phone. For those with ‘out of date’ phone 
numbers or without a number listed, best efforts were made to obtain this information 
via the systems already in place for the research. For those that consented following a 
telephone contact, a package was mailed out, containing a postage paid return 
envelope. This method of recruitment began in April 2018 and ceased in October 
2018. 
3. Partners of ICD patients who were not part of the first eight families identified for 
study invitations sometimes had chance encounters with the research team. This was 
often due to centralized medical services and the close-knit ARVC community in NL. 
During these encounters, if the partner was interested, the research project was 
discussed, and a study package sent by post if requested. This method of recruitment 
was utilized from September 2017 to October 2018. 
3.4.3. INCLUSION/EXCLUSION CRITERIA 
 
The inclusion criteria included being a partner of an ICD patient, over the age of 18 and 
able to complete the surveys. Of the 59 spouses, three did not reside in the province and were 
excluded. Seventeen of the remaining 56 were contacted by the research team through the 
cardiac clinic during their partner’s ICD appointment. Of the remaining 39, four were deceased, 
contact information was not available for four, 11 did not have a connection to the research team, 
and a clinical decision was made not to contact another two due to concerns about causing 
distress, as the team were aware of major family issues at the time of this research. This left 15 
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partners that were contacted by phone. See Figure 4.1 for detailed flowchart of study population, 
recruitment and inclusion/exclusion.  
 
3.5 DATA COLLECTION 
 
3.5.1 PATIENT ENGAGEMENT MEETING QUALITATIVE 
 
During the patient engagement meeting, a largely unstructured, fluid discussion took 
place. The research project was explained to the group. The group was then given the 
opportunity to critique the study. This conversation naturally led to the group discussing their 
experiences of living with ARVC in the family, and in particular, their experiences with mental 
health challenges and care provision. Information gathered from this meeting was used to both 
inform the study protocol and included in the results section of this thesis as it pertains to the 
impact of living with an ICD on the family unit. 
3.5.2 QUANTITATIVE 
 
Study packages were returned by participants either in person or through the mail. Retuned 
packages contained the completed scales. Although qualitative data was not a focus for this 
project, a small amount was collected from open comments on returned surveys. Although there 
was no prompt or question asking for additional information on the packages, some respondents 
chose to include their thoughts. There was not enough data via this method for a full coding 
analysis and creation of a framework; however, it is included in this thesis as it adds to the 
understanding of how families experience this disease and treatment. 
From the database used to identify participants (HREB 00-176), clinical and demographic 
data was available for ICD patients. This data was used to explore whether partners’ scores on 
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the questionnaires were related to disease severity in the ICD patient and the family. From the 
1900+ variables in the dataset, the research team focused on nine that were thought to be the 
most relevant to this study. Both the literature and the clinical experience of the team suggested 
variables were likely to be related to the partner’s mental health. They are as follows. 
• Age 
• Sex 
• Number of Hospitalizations of Partner with ICD  
• Age at which the ICD was implanted in partner  
• Number of appropriate shocks experienced by partner with an ICD  
• Number of inappropriate shocks experienced by partner with an ICD 
• Did the partner with the ICD go on to have a heart transplant  
• Did the partner with an ICD have a 1st Degree relative with either SCD/Heart 
Transplant/Accident(possible SCD)/Other at time of presentation  
• Time from ICD implant 
From the larger dataset, a smaller de-identified dataset with the above defined variables was 
created and used for the purposes of analysis. 
3.6 DATA STORAGE 
 
 The data collected became part of the large previously existing dataset (HREB 00-176) 
Physical copies of retuned surveys were filed in a locked cabinet behind a locked door in Dr. 
Hodgkinson’s file room. Survey scores were entered digitally into the dataset which is kept on a 




3.7.1 ETHICS APPROVAL 
This study was approved by the HREB under Application for General Research at MUN under 
reference number HREB#20171983. Full board approval was granted on July 14, 2017. 
(Appendix 7) 
3.7.2 ETHICAL CONSIDERATIONS 
 
Ethical considerations were given to each step of this project. When this study was being 
planned, there were concerns that this population may be over studied. As noted, many of these 
families have been part of research studies since the 1980’s. This disease is also life altering and 
families may have suffered distress and tragedy. Upon consultation with those who have worked 
closest with the families, it was decided that with appropriate risk mitigation, the potential 
benefits of this study outweighed the potential harm. Further, the patient engagement planning 
session revealed family members’ support of a project focused on mental health in ARVC. 
Strategies to mitigate risk included not contacting potential participants that were likely 
under duress. If the research team was aware of recent family tragedy, if the individual was at 
risk of self-harm, or any similar circumstance, the individual was not approached to be a part of 
the study. For those who were approached to participate, a clear cover letter was created that 
ensured individuals knew participation in the study was voluntary and would not impact their 
health care. Additionally, the research team identified that thinking about one’s mental health, 
particularly in the context of this disease may be distressing. Included the study packages were 
mental health supports for both acute and chronic needs. Finally, the research team recognized 
the possibility of individuals scoring high (or in other words, the potential indicator of severe 
mental health symptoms) on one or more of the scales. If a participant scored within the highest 
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category on any of the scales, they were contacted by Dr. Hodgkinson and after consenting, were 
contacted by Dr. Orzylowski, a psychiatrist or, Drs. Paulin or Connors, their cardiologists, to 
discuss their concerns further. Guidance and referrals for mental health services were given as 
appropriate. 
3.8 STATISTICAL ANALYSES 
 
 All quantitative data were analyzed using SPSS v.25 for Mac. A significance level of 
p<0.05 was used for all statistical analyses. Participant responses on each scale were scored as 
per the scoring guidelines outlined under “Measures”. Additionally, participants who scored 
within the above outlined thresholds on the scale were marked positive for that mental health 
outcome. This gave each participant a score and a categorization of yes or no for anxiety, 
depression, and PTSD. 
3.8.1 DESCRIPTIVE ANALYSES  
 Descriptive statistics and frequencies were used to determine the demographics of 
respondents, survey response rates and mental health scale data. 
3.8.2 UNIVARIATE ANALYSES 
 Associations between scale scores and continuous clinical and demographic data were 
analyzed using correlations. Continuous variables were: Age, PHQ-9 score of partner with ICD, 
SAS score of partner with ICD, PCL-C score of partner with ICD, number of hospitalizations of 
partner with ICD, age at which the partner was implanted with the ICD, number of appropriate 
shocks experienced by partner with ICD, number of inappropriate shocks experienced by partner 
with ICD, time from ICD implantation. Normality for each variable was assessed using a 
Shapiro-Wilk test which test. Variables were analysed using Pearson Correlation coefficient or 
the non – parametric Spearman correlation coefficient. 
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 Relationships between scale scores and categorical variables were also explored. 
Categorical variables were sex (1=male, 2=female), Did the partner with an ICD go on to have a 
heart transplant (1=yes, 2=no), and did the partner with an ICD have a first degree relative with 
either SCD/Heart Transplant/Accident (possible SCD)/Other at time of presentation (1=yes, 
2=no). Shapiro-Wilk was again used to test for normality. Normally distributed variables were 
analysed using a t-test and non-normal were analysed using the non-parametric equivalent, 
Mann-Whitney U. 
3.8.3 COMPARING BETWEEN GROUPS IN THE TOTAL STUDY POPULATION 
Differences in scale score were examined across the three groups: partners, ICD patients, 
and negative relatives. Normality was assessed using Shapiro-Wilk. Variables were assessed 
using Analysis of Variance (ANOVA) or the non-parametric equivalent Kruskall-Wallis. If a 
significant difference was found, a Dunn-Bonferroni post hoc test was used to determine where 
the significance originated.  
3.8.4 COMPARING PARTNERS OF ICD RECIPIENTS AND THE GENERAL POPULATION 
 
Prevalence of anxiety, depression and PTSD were analysed in partners as compared to 
the general population. The prevalence for partners was determined from those who scored 
above the threshold on a scale and were considered positive for that condition. Prevalence in the 
general population was available from Statistics Canada and literature. To provide greater 
strength, the higher ‘lifetime prevalence’, of a condition was used rather than a 12-month 
prevalence. A binomial test was chosen rather than a chi squared test because some expected 
frequencies for all three questionnaires was less than five.  
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CHAPTER 4. RESULTS 
 
4.1 PATIENT ENGAGEMENT MEETING 
Two ARVC families were represented in the patient engagement session. From the first 
family, an ICD patient attended. From the second, two ICD patients, one assumed carrier without 
an ICD, one partner, and two negative siblings attended, representing a range of lived experience 
with ARVC. Also present were members of the research team: Dr. Holly Etchegary, Dr. Kathy 
Hodgkinson, Ms. Natalie Butt, and Ms. Mary Walsh.  
During the patient engagement meeting, conversations covered the disease itself, 
diagnosis, supports (or lack thereof), family dynamics and mental health challenges associated 
with ARVC specifically. The ICD patient from the first family recounted feeling good about the 
diagnosis mainly because it explained previously unexplained deaths in the family. The family 
was offered a psychologist appointment at the time of diagnosis but declined. Later in the course 
of disease, however, the family was experiencing major mental health concerns, including 
suicidal ideation, but at that time did not know where to turn for support. This experience 
highlighted that mental health support may be required post-diagnosis.  
Family two felt they were inadequately prepared for the physical and mental toll of the 
ICD treatment and noted they were not offered psychological support at all, unlike family one. 
An ICD patient from family two remarked that the only information they received was a tiny 
booklet and his partner (female, 50) responded, “We were trying to figure out if we should be 
worried, asking questions, but we just didn’t know.” An ICD patient from family two expressed 
that they didn’t feel the need for mental health supports at the time of diagnosis, they felt the 
needed more information about the disease itself and treatment. The ICD patient from family one 
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(female, 64) responded, “You may not need that kind of support at the beginning, but you could, 
later down the road. I had no idea what was coming.” The patient engagement session confirmed 
family members’ support of research focused on the mental health challenges associated with 
living with a disease like ARVC. They also supported a systematic approach to the provision of 
mental health care and resources.  
Overall, there were a few key themes from this meeting. First was the need to address the 
lack of information about the disease and treatment itself provided at time of diagnosis and ICD 
surgery. Second was the need for mental health supports both at time of diagnosis and at follow 
up intervals. The third was overwhelming confirmation that ARVC and ICD treatment impacts 















4.2 STUDY POPULATION 
 
Figure 4.1 Flowchart of Participant Recruitment  
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For the larger study, 313 individuals were identified as potential participants: 103 ICD 
patients, 148 negative relatives, and 59 partners. See Figure 4.1 for a detailed recruitment 
flowchart of partners. See Appendix 8 for recruitment flowchart of larger project including ICD 
recipients and negative relatives. The focus of the current project and subsequent analyses will 
be the partners. Of the 59 potential participants, four were deceased and three were not living in 
the province, which left a possible 52. However, contact was made with some partners living 
outside the province. Of those living in the province, three were no longer a partner of a patient 
with and ICD, 11 had no connection to the research team, two were not contacted due to clinical 
decisions made by the research team, and contact information was not available for four. From 
the remaining 32, 17 were contact through the ICD clinic when they attended with their partner. 
Four chose not to return the surveys, which left 13 surveys completed through the clinic. The 15 
who did not attend the clinics were contacted by phone; two chose not to participate or return the 
phone call and five requested a survey but did not return it. This left eight surveys completed by 
phone contact and returned by mail. The final mode of recruitment was by chance. There were 
ten partners from families outside of the first eight families that had contact with the research 
team; five of them did not return surveys, leaving five partners contacted by chance who 
completed the surveys. In total, 26 partners completed surveys and comprise the study sample.  
4.3 DESCRIPTIVE PROFILE OF THE PARTICIPANT PARTNERS OF ICD RECIPIENTS   
Table 4.1: Participant Demographics 
Age Range 19-69 
Mean(SD) 51(13) 




The average age of partners was 51 years old and ranged from 19 to 69. There was an 




Table 4.2: Participant Response Rates by Method of Contact 
Method of Contact Number of Surveys 
Given 
Number of Surveys 
Retuned 
Response Rate  
(%) 
Cardiac Clinic 17 13 76 
Phone 15 9 60 
By Chance 10 5 50 
Total 42 26 62 
 
Table 4.2 outlines the response rates of participants by method of contact. The best 
response rate was from partners seen at the clinic when attending with their partner, the ICD 
patients (76%), followed by those contacted through the phone and subsequently mailed a 
package (60%); the lowest rate was found in those contacted by chance who later received a 
mailed package (50%). The overall response rate for all participants was 62%. 
 
4.4 DESCRIPTIVE PROFILE OF QUESTIONNAIRE RESPONSES 
Table 4.3: Questionnaire Responses Scored 
Questionnaire N Mean(SD) Minimum Maximum Clinical Significance Highest Category 








SAS 26 40 (9.8) 25 60 45 9  (35%) 75 1(4%) 
PCL-C- 26 37 (14) 17 63 36 17(65%) 44 9(35%) 
PHQ-9  26 4.9 (5.3) 0 20 10 3(12%) 20 2(8%) 
 
Table 4.3 describes the range of scores and presents the mean for each of the three mental 
health measures. All participants (n=26) completed all three questionnaires. The average SAS 
ranged from 25 to 60 with a mean of 40 (SD=9.8). The mean of the PCL-C questionnaire was 37 
 38 
(SD=14), with scores ranging from 17 to 63. The scores on the PHQ-9 questionnaire ranged from 
zero to 20 and had a mean of 4.9 (SD=5.3). Of the study sample (n=26), the number of 
participants above the threshold for anxiety, PTSD, and depression were nine, 17, and three, 
respectively. The number of participants that scored in the highest category for anxiety, 
depression and PTSD were one, nine, and two, respectively.  
4.5 ANALYSES OF QUESTIONNAIRE SCORES, CLINICAL AND DEMOGRAPHIC DATA 
 
Relationships between the questionnaire scores and continuous clinical and demographic 
data were first explored using correlational analysis. Normally distributed variables were 
analysed using Pearson Correlation Coefficient and reported using r. These were: SAS score, 
PCL-C score, age, PHQ-9 score of partner, SAS score of partner, PCL-C score of partner, Age at 
which the ICD was implanted in partner. Variables that were non-normally distributed were 
analysed using the non-parametric Spearman’s correlation coefficient and reported using rS. 
These variables were: PHQ-9 score, number of hospitalizations of partner with ICD, number of 
appropriate shocks experienced by partner with an ICD, number of inappropriate shocks 
















Table 4.4: Correlations for Questionnaire Scores 
 Scale Missing 
(%) Variable PHQ-9 PCL-C SAS 











































Number of Hospitalizations of 








Age at which the ICD was 








Number of appropriate shocks 









Number of inappropriate shocks 
















*correlation is significant at the p=0.05 level (2-tailed) 
The PHQ-9 score was significantly correlated with the other two scores, PCL-C score 
(rS(24)=0.469, p=0.016)) and SAS score (rS(24)=0.632, p=0.001). It was also significantly 
correlated with the number of appropriate shocks experienced by the partner with an ICD 
(rS(24)=0.518, p=0.011).  
As noted, the PCL-C score was significantly correlated with both the anxiety and 
depression scales. There were also significant positive correlations with the PCL-C score of the 
partner with an ICD (r(24)=0.593, p=0.002), number of hospitalizations of the partner with an 
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ICD (rS(24)=0.407, p=0.039), and the number of appropriate shocks experienced by the partner 
with an ICD (rS(24)=0.564, p=0.005). 
The SAS, as noted above, had significant correlations with the PHQ-9 and PCL-C. There 
were no other significant correlations.  
Relationships between categorical clinical and demographic data and questionnaire 
scores were also explored. These variables were: sex, did the partner with an ICD go on to have a 
heart transplant, and did the partner with an ICD have a first degree relative with SCD at time of 
presentation. The questionnaire scores were assessed for normality again using Shapiro-Wilk 
test. The PHQ-9 scores were distributed normally for all variables but sex. The PCL-C scores 
were distributed normally for all the variables. The SAS scores were distributed normally only 
for the variable, did the partner with an ICD go on to have a heart transplant. Normally 
distributed data was analysed using a t-test and reported using t. Non-normally distributed data 
was analysed using the non-parametric Mann-Whitney-U test and reported using the p-value. 
 
Table 4.5: Analysis for Categorical Variables and Questionnaire Scores 
 Scale Missing 
(%) Variable PHQ-9 PCL-C SAS 
Sex p=0.212 t(24)=-2.012, 
p=0.056 
p=0.118 0 
Did the partner with an ICD 









Did the partner with an ICD 
have a 1st Degree relative 
with either SCD/Heart 
Transplant/Accident(possible 







*significant at the p=0.05 level 
 
 Table 4.5 summarizes the analysis of categorical variables and questionnaire scores. 
There were no significant relationships with any of the categorical variables and either the PHQ-
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9 or the SAS. There was a significant relationship, however, between the PCL-C and whether the 
partner with an ICD went on to have heart transplant.  
4.6 ANALYSES COMPARING QUESTIONNAIRE SCORES AMONG PARTNERS, ICD 
PATIENTS, AND NEGATIVE RELATIVES 
 
Table 4.6 summarizes the mean scores of the three questionnaires for the study groups: 
participants of this study, their partners with ICDs, and the partner’s negative relatives.  
Table 4.6: Summary of Scores for Partners, Negative Relatives, and ICD Patients 
  PHQ-9 SAS PCL-C 
Partner Mean Score 
(SD) 





4.6 (3.8) 37 (9.6) 27 (8.5) 
ICD Patient Mean Score 
(SD) 
7.3 (6.4) 44 (12) 33 (13) 
 
The three score distributions (PHQ-9, SAS, PCL-C) for each group (Partner, ICD patient, 
negative relative) were checked for normality using the Shapiro-Wilk test. Scores were not 
normally distributed, and a Kruskal-Wallis test was used to compare medians. Table 4.7 
summarizes the results from the test.  
 
Table 4.7: Summary of Kruskall-Wallis Test Between Groups for Scores  
 PHQ-9 SAS PCL-C 
p-value 0.145 0.038* 0.037* 
* significant at the p=0.05 level 
 
 The Krukal-Wallis test revealed no significant differences among the three groups in the 
PHQ-9 Scores. There were significant differences among the groups in both SAS scores and 
PCL-C scores. Post hoc Dunn-Bonferroni analysis in the SAS scores revealed a significant 
difference (p=0.038) between the ICD patients (x=44(12)) and Negative relatives (x=37(9.7)), 
such that ICD patients scored higher on the anxiety measure.  The post hoc Dunn-Bonferroni for 
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the PCL-C score revealed a significant difference (p=0.035) between partners and negative 
relatives, such that partners of patients with an ICD scored higher on the posttraumatic stress 
measure.  
4.7 ANALYSES COMPARING PREVALENCE OF ANXIETY, DEPRESSION, AND PTSD OF 
PARTNERS AND THE GENERAL POPULATION. 
 
Binomial tests were used to compare the proportion of participants who met the 
questionnaires’ threshold for depression, anxiety, and PTSD with general population rates in 
Canada (Table 4.8). The proportion of the study sample meeting the threshold for clinically 
significant depression did not differ from general population rates. The prevalence of anxiety in 
partners (34.6%) was significantly (p<0.001) higher than that of the general population (8.7%). 
The prevalence of PTSD in partners (65.3%) was also significantly (p<0.001) higher than that of 
the general population (9.2%)  
 
Table 4.8 : Summary of Binomial Test for Comparison with General Populations 





Do they meet the 
threshold for 
Depression(score10) 
No 23 0.885 0.887 0.576 
Yes 3 0.115  
Do they meet the 
threshold for Anxiety 
(score45) 
No 17 0.654 0.913 <0.001 
Yes 9 0.346  
Do they meet the 
threshold for 
PTSD(score36) 
No 9 0.346 0.903 <0.001 
Yes 17 0.654  
 
4.8 OPEN-ENDED COMMENTS 
Two respondents provided open comments about their experiences with ARVC and ICDs in the 
family. These correspond with scale data and help illustrate the burden of ARVC on partners.  
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“I remember prior to her being diagnosed with ARVC there would be times when she was 
just sitting at home watching TV and her heart would start to race 120-130 BPM and 
higher and she wasn’t doing anything strenuous. After several bouts of this and a number 
of trips for her doctor and ever so many tests and it was confirmed that she does indeed 
have ARVC – the learning process begins. Well the first lesson is there is no cure, ok so 
how do you treat it? Again, google became my best friend.” -Male, 52 
 
This partner went on to describe several lifestyle adjustments he and his partner have made - 
from being aware of ambient temperature due to circulation issues, to preparing for ICD shocks:  
“From here, there has been more adjustments and changes to [ICD patient]’s lifestyle 
and habits all because of ARVC, some small some not so small and it’s a constant 
learning process of what she can and cannot do. To many of us, one of the small changes 
would be welcome, but with the many small ones and some large lifestyle changes it can 
be overwhelming and a constant challenge to live with ARVC.” 
 
Another respondent described similar impacts: 
“First was to explain my fear –Sword of Damocles. Constant threat of an event or 
change in the heart condition of my family. I push these thoughts away. Seeing the 
defibrillator go off numerous times and the fear and emotional stress on your partner is 
extremely hard. But you have to be strong for the other family members.” -Male, 69 
 
While qualitative data was not a focus of this project, these comments help illustrate the impact 









CHAPTER 5. DISCUSSION 
 
 This study is the first quantitative study of the mental health sequale in partners of 
patients with ICDs in the TMEM43 p.S358L population.  
 The response rates for the surveys were on par with existing literature. A systematic 
review of the responses of surgery patients found in-person surveys yield a response rate of 76% 
which was the exact rate of our surveys completed in the cardiac clinic.70 The study also found 
responses by mail to be 65% where our response by mail ranged from 50%-60%.  
 The mean score for anxiety (40) fell within the normal range (<45), while the mean score 
for depression (4.9) was borderline between minimal (0-4) and mild (5-9). The mean PTSD score 
(37) fell above the threshold determined to indicate PTSD positive (36). For each of the mental 
health surveys, there is subset of partners who scored above the threshold for clinically 
significant symptoms. For anxiety, clinically significant symptoms were found in 35% of 
partners which is less than the rate of 42-48% found in the literature.41,46,50 Similarly the rate of 
depression (12%) was on the lower end of the rates of 14-29% from the literature. There were no 
studies of PTSD in partners to compare with this study’s rate of 65%. Within this subset of 
participants scoring above the threshold for clinical significance, there was a smaller but 
important portion of partners that scored within the highest category for anxiety (4%), depression 
(8%), and PTSD (35%). This study population had lower rates of anxiety and depression than the 
general partners of ICD patients, which may be due to the multigenerational nature of the 
disease. Many of the families have been dealing with the effects for years and may have 
developed protective coping mechanisms. However, there is a very high rate of PTSD that 
indicates the mental health challenges of this population manifest as PTSD symptoms rather than 
anxiety and depression. When considering the lethality of the disease and the that an appropriate 
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shock is considered an aborted SCD, it stands to reason that witnessing an ICD patient receive a 
shock could be a traumatic event. These findings, despite being from a small pilot study, 
demonstrate the uniqueness of mental health experiences of partners in the TMEM43 p.S358L 
families and highlight the necessity to fill the existing gap in the literature for this population. 
There were two missing values in the three scale scores of partners with ICDs and three 
missing in the number of appropriate and inappropriate shocks of the partner with an ICD. The 
missing values for are due to two reasons. The first is not all respondent’s partners chose to 
participate so there were two partners for whom there are no questionnaire scores. However, 
clinical and demographic data for these ICD patients could be extracted from the database for 
which they had previously given consent. The second is geographical constraints. Some ICD 
patients were treated outside of NL, which meant their medical histories were not readily 
available.  
 Scores for anxiety, depression, and PTSD were all positively significantly correlated with 
one another, which is unsurprising since all three scales measure some aspect of mental health. 
Thus, if a participant scored high on either score, they were likely to score high on the other two. 
Anxiety scores were only significantly correlated to one variable: number of appropriate shocks 
experienced by the ICD patient. This corresponds with the literature of partners of ICD patients 
with shocks having higher rates of anxiety than those who have not experienced shocks.50 
Interestingly, no significant association was found between anxiety scores and ‘number of 
inappropriate shocks experienced by the partner with the ICD’. This may suggest that the anxiety 
comes from a knowledge of the appropriate shock being an aborted death, rather than the shock 
itself.  Of the two studies from the literature that looked at sex, neither found differences in rates 
of depression and one found females had higher levels of anxiety.41,44 This study found no 
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differences between scores of anxiety or depression when stratified according to sex. When 
anxiety and depression were measured at different points of time in the literature, it was 
generally found that symptoms of both decreased over time.44,49,51 The current study was cross 
sectional and did not measure change in mental health scores over time. The variable of ‘time 
from implant’ gives some indication of how long a partner has been living with an ICD patient, 
but is not a true measure of an individual’s mental health at two points in time. This variable was 
not significantly related to either anxiety, depression, or PTSD and did not indicate any change 
in symptoms over time as found in the literature. 
 Partners’ PTSD scores were significantly associated with many variables and there is no 
literature with which to compare these novel findings. The PTSD score of partners was 
significantly positively related to the ‘PCL-C score of partner with ICD’, ‘number of 
hospitalizations of partner with the ICD’, ‘number of appropriate shocks experienced by the 
partner with the ICD’, and ‘did the partner with an ICD go on to have a heart transplant’. It is 
likely all these variables are related and may even be confounding; however, without enough 
statistical power for linear regression this cannot be confirmed. Certainly, the findings appear to 
have face validity. When an ICD patient experiences a shock from their device, their partner may 
be present. With an increasing number of shocks, the likelihood that a partner will witness the 
event increases. Additionally, the ICD patient may lose consciousness during the event, while the 
partner observes. Also, with an increasing number of shocks, the disease severity is likely worse 
which would be related to the ICD patient needing a transplant. This is similar to the finding to 
the study on partners of epilepsy patients where higher levels of PTSD in the partners was 
associated with severity of the seizure.9 While the study did not define severity it is likely to 
include loss of consciousness. This study, while small, indicates significant PTSD symptoms 
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within the partner population and subsequently the need for mental health interventions. With the 
paucity of literature currently available on partners’ experiences with PTSD, further research is 
needed. Future studies that explore the risk factors associated with PTSD could help identify at 
risk individuals and inform intervention models.   
 In comparing the three groups from the larger study, partners, ICD patients, and negative 
relatives, significant differences in survey scores were found for anxiety and PTSD but not 
depression. Further analysis of the anxiety scores revealed the significance was due to the 
difference in ICD patients and negative relatives, meaning that the ICD patients had higher levels 
of anxiety. This is not consistent with the literature, where partners were found to have higher or 
equal levels of anxiety to the ICD patient.40,41,42,44 The lethal and hereditary nature of the disease 
make it challenging to differentiate what effects are due to the ICD treatment and what effects 
are due to the disease itself. As previously discussed, the lower levels of anxiety in the partners 
could be due to developed coping mechanisms. However further research is necessary to 
determine whether these findings are artifact from the small sample size or would remain 
consistent in a larger study. Determining whether anxiety is an issue within this population is 
important to inform patient education and healthcare provision for the TMEM43 p.S358L 
partners and their families. 
The significance for the PTSD scores comes from the difference in scores for the partners 
and negative relatives. This is an interesting finding that partners are experiencing higher rates of 
PTSD than the ICD patients themselves. This may be because some patients lose consciousness 
before the shock and are therefore not remembering the actual event whereas their partner may 
be witnessing it. Findings point to the very real potential for partners of ICD patients to develop 
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PTSD and future research that confirms this finding will be critical to inform healthcare 
provision and policy regarding these family members.  
 Comparisons between the rates of mental health between partners and the general 
population revealed significant differences in anxiety and PTSD, but not depression. Partners’ 
experiences of higher rate of anxiety and PTSD can likely be attributed being a part of a family 
living with a potentially fatal disease and everything that it encompasses. The treatment for the 
disease, while lifesaving, can carry physical and psychosocial burdens that are felt by the partner 
as well. Additionally, the disease is autosomal dominant and any biological children they and 
their partner conceive have a 50% chance of inheriting the disease. While this study cannot 
elucidate causation the findings indicate that the partners in the TMEM43 p.S358L population 
have a unique mental health burden and support needs as compared to the general population. 
 While qualitative data was not the focus of the project, the small amount collected did 
correspond with the literature, as did the themes arising from the patient engagement session. 
The concept of ICD treatment having psychological implications for the entire family unit is 
found in other research.39,40,47 In the literature, partners acknowledged feelings of anxiety, fear 
and guilt which were echoed by partners in this study. A topic that was not found in the literature 
but was noted at the patient engagement meeting and in open ended responses was the lack of 
information patients and their families received at the time of diagnosis and at ICD implantation. 
This finding is important and could help inform the creation of patient and partner-facing 
educational resources, as well as help clinicians provide anticipatory guidance to patients and 





 This study had several limitations. First the sample size (n=26) is quite small, which 
limited the power for statistical analysis. However, this was a pilot study and did reveal 
significant mental health sequale within the TMEM43 p.S358L population partners. Further 
studies with larger sample sizes can further investigate the extensive variables available in the 
TMEM43 dataset. The next limitation was the dataset itself. It is not directly connected to 
medical records and is only updated when research projects occur. This meant that information 
may have been outdated and some phone numbers were no longer in service. As previously 
discussed, the TMEM43 p.S358L population in NL is unique. The participants in the study all 
come from families affected by the same gene variant which creates a very homogenous sample 
that is not easily generalizable to other ARVC populations. Unfortunately, however, research 
using other ARVC and cardiac populations have also shown negative mental health outcomes in 
partners.  
 As most adult patients with ARVC due to a TMEM43 p.S358L mutation receive an ICD 
as treatment it is difficult to differentiate the effects of the ICD and the disease itself. The finding 
of higher levels of PTSD symptoms being associated with appropriate shocks rather than 
inappropriate shocks suggests the PTSD may come from witnessing a traumatic event (aborted 
SCD) rather than the device function itself. Further studies to determine risk factors and 
elucidate the exact source of the mental health symptoms would be useful. 
The cross-sectional design of this study means we cannot elucidate the partner’s ICD as a 
cause for the findings. The measures used in this study were self-report measures, that are 
susceptible to respondent bias and do not equate to a physician’s diagnosis of mental health 
conditions. Self-report measures were used because it was not feasible to have all participants 
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see a psychiatrist and best efforts were made to have the measures used comparable to other 
studies. Additionally, with any voluntary study there is the risk for respondent bias. It is possible 
that people with more severe mental health symptoms did not respond for fear of stigma and also 
possible that people with good mental health may have felt they are not impacted and did not 
respond. Respondent bias is likely to be present in the research teams’ decision not to contact 
those who have suffered a recent family tragedy or were at risk of self-harm.  
5.2 CONCLUSION 
 
 This pilot study examined the symptoms of anxiety, depression and post-traumatic stress 
in the partners of TMEM43 p.S358L mutation positive individuals with ICD treatment. This was 
the first quantitative study of mental health symptoms in the Newfoundland ARVC population.  
 Findings in this study indicate that partners in this specific population have slightly lower 
rates of anxiety and depression than found in the literature for partners in the wider ICD 
treatment population. The rate of depression in partners was not significantly higher than the 
general population but the rate of anxiety was significantly higher. Rates of PTSD in the partners 
was higher than their partner with an ICD, their negative relatives and the general population. 
Significant associations were found between the survey scores for anxiety, depression, and 
PTSD. Number of appropriate shocks was also significantly associated with higher scores of 
depression and PTSD.  
 This study highlights that although the partners of the ICD recipients are not genetically 
burdened by the disease, their mental health is significantly affected. This suggests that partners’ 
mental health should be considered, and appropriate supports given at the time of ICD treatment. 
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 Future studies could explore risk factors and mental health interventions to determine the 
best way to support partners. Further studies of PTSD in partners of the wider ICD population 
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APPENDIX 1: DIAGNOSIS OF ARRHYTHMOGENIC RIGHT 
VENTRICULAR CARDIOMYOPATHY/DYSPLASIA MODIFIED 
TASK FORCE CRITERIA 
 
Table 1: Comparison of Original and Revised Task Force Criteria3 
 
  Original Task Force Criteria Revised Task Force Criteria 
I. Global or regional dysfunction and structural 
alterations* 
  
    Major   
    By 2D echo: 
• Severe dilatation and reduction 
of RV ejection fraction with no (or 
only mild) LV impairment 
• Regional RV akinesia, dyskinesia, or aneurysm 
• and 1 of the following (end diastole): 
— PLAX RVOT ≥32 mm (corrected for body size 
[PLAX/BSA] ≥19 mm/m2) 
• Localized RV aneurysms 
(akinetic or dyskinetic areas with 
diastolic bulging) 
— PSAX RVOT ≥36 mm (corrected for body size 
[PSAX/BSA] ≥21 mm/m2) 
• Severe segmental dilatation of 
the RV 
— or fractional area change ≤33% 
  By MRI: 
• Regional RV akinesia or dyskinesia or dyssynchronous RV 
contraction 
• and 1 of the following: 
— Ratio of RV end-diastolic volume to BSA ≥110 
mL/m2 (male) or ≥100 mL/m2 (female) 
— or RV ejection fraction ≤40% 
By RV angiography: 
• Regional RV akinesia, dyskinesia, or aneurysm 
    Minor   
    By 2D echo: 
• Mild global RV dilatation and/or 
ejection fraction reduction with 
normal LV 
• Regional RV akinesia or dyskinesia 
• and 1 of the following (end diastole): 
— PLAX RVOT ≥29 to <32 mm (corrected for body size 
[PLAX/BSA] ≥16 to <19 mm/m2) 
• Mild segmental dilatation of the 
RV 
 
3 Reprinted from, Circulation, 121/13, Frank I. Marcus, William J. McKenna, Duane Sherrill, et al., Diagnosis of 
Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia, 1533-1541, 2010, with permission from Wolters 
Kluwer Health, Inc. 
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Table 1: Continued 
 
  Original Task Force Criteria Revised Task Force Criteria 
 
• Regional RV hypokinesia — PSAX RVOT ≥32 to <36 mm (corrected for body size 
[PSAX/BSA] ≥18 to <21 mm/m2) 
— or fractional area change >33% to ≤40% 
  By MRI: 
• Regional RV akinesia or dyskinesia or dyssynchronous RV 
contraction 
• and 1 of the following: 
— Ratio of RV end-diastolic volume to BSA ≥100 to <110 
mL/m2 (male) or ≥90 to <100 mL/m2 (female) 
— or RV ejection fraction >40% to ≤45% 
II. Tissue characterization of wall   
    Major   
  • Fibrofatty replacement of 
myocardium on endomyocardial 
biopsy 
• Residual myocytes <60% by morphometric analysis (or <50% 
if estimated), with fibrous replacement of the RV free wall 
myocardium in ≥1 sample, with or without fatty replacement of 
tissue on endomyocardial biopsy 
    Minor   
    • Residual myocytes 60% to 75% by morphometric analysis (or 
50% to 65% if estimated), with fibrous replacement of the RV 
free wall myocardium in ≥1 sample, with or without fatty 
replacement of tissue on endomyocardial biopsy 
III. Repolarization abnormalities   
    Major   
    • Inverted T waves in right precordial leads (V1, V2, and V3) or 
beyond in individuals >14 years of age (in the absence of 
complete right bundle-branch block QRS ≥120 ms) 
    Minor   
  • Inverted T waves in right 
precordial leads (V2 and V3) 
(people age >12 years, in absence 
of right bundle-branch block) 
• Inverted T waves in leads V1 and V2 in individuals >14 years 
of age (in the absence of complete right bundle-branch block) 
or in V4, V5, or V6 
• Inverted T waves in leads V1, V2, V3, and V4 in individuals 
>14 years of age in the presence of complete right bundle-
branch block 
IV. Depolarization/conduction abnormalities   
    Major   
  • Epsilon waves or localized 
prolongation (>110 ms) of the 
QRS complex in right precordial 
leads (V1 to V3) 
• Epsilon wave (reproducible low-amplitude signals between 
end of QRS complex to onset of the T wave) in the right 




  Original Task Force Criteria Revised Task Force Criteria 
    Minor   
  • Late potentials (SAECG) • Late potentials by SAECG in ≥1 of 3 parameters in the 
absence of a QRS duration of ≥110 ms on the standard ECG 
• Filtered QRS duration (fQRS) ≥114 ms 
• Duration of terminal QRS <40 μV (low-amplitude signal 
duration) ≥38 ms 
• Root-mean-square voltage of terminal 40 ms ≤20 μV 
• Terminal activation duration of QRS ≥55 ms measured from 
the nadir of the S wave to the end of the QRS, including R′, in 
V1, V2, or V3, in the absence of complete right bundle-branch 
block 
V. Arrhythmias 
     Major  
    • Nonsustained or sustained ventricular tachycardia of left 
bundle-branch morphology with superior axis (negative or 
indeterminate QRS in leads II, III, and aVF and positive in lead 
aVL) 
    Minor 
  • Left bundle-branch block-type 
ventricular tachycardia (sustained 
and nonsustained) (ECG, Holter, 
exercise) 
• Nonsustained or sustained ventricular tachycardia of RV 
outflow configuration, left bundle-branch block morphology 
with inferior axis (positive QRS in leads II, III, and aVF and 
negative in lead aVL) or of unknown axis 
 • Frequent ventricular extrasystoles 
(>1000 per 24 hours) (Holter) 
• >500 ventricular extrasystoles per 24 hours (Holter) 
VI. Family history  
               Major  
 • Familial disease confirmed at 
necropsy or surgery 
• ARVC/D confirmed in a first-degree relative who meets 
current Task Force criteria 
  • ARVC/D confirmed pathologically at autopsy or surgery in a 
first-degree relative 
• Identification of a pathogenic mutation† categorized as 
associated or probably associated with ARVC/D in the patient 
under evaluation 
    Minor  
 • Family history of premature 
sudden death (<35 years of age) due 
to suspected ARVC/D 
• History of ARVC/D in a first-degree relative in whom it is not 
possible or practical to determine whether the family member 
meets current Task Force criteria 
 • Familial history (clinical diagnosis 
based on present criteria) 
• Premature sudden death (<35 years of age) due to suspected 
ARVC/D in a first-degree relative 
 
Table 1: continued 
  Original Task Force Criteria Revised Task Force Criteria 
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  • ARVC/D confirmed pathologically or by current Task Force 
Criteria in second-degree relative 
PLAX indicates parasternal long-axis view; RVOT, RV outflow tract; BSA, body surface area; PSAX, parasternal 
short-axis view; aVF, augmented voltage unipolar left foot lead; and aVL, augmented voltage unipolar left arm 
lead. 
Diagnostic terminology for original criteria: This diagnosis is fulfilled by the presence of 2 major, or 1 major plus 2 
minor criteria or 4 minor criteria from different groups. Diagnostic terminology for revised criteria: definite 
diagnosis: 2 major or 1 major and 2 minor criteria or 4 minor from different categories; borderline: 1 major and 1 
minor or 3 minor criteria from different categories; possible: 1 major or 2 minor criteria from different categories. 
*Hypokinesis is not included in this or subsequent definitions of RV regional wall motion abnormalities for the 
proposed modified criteria. 
†A pathogenic mutation is a DNA alteration associated with ARVC/D that alters or is expected to alter the encoded 
protein, is unobserved or rare in a large non-ARVC/D control population, and either alters or is predicted to alter the 






























APPENDIX 2: ZUNG SELF-RATING ANXIETY SCALE 
 
Table 3: The Self-Rating Anxiety Scale(SAS)4 












1. I feel more nervous and anxious than usual.     
2. I feel afraid for no reason at all.     
3. I get upset easily or feel panicky.     
4. I feel like I'm falling apart and going to 
pieces.  
    
5. I feel that everything is all right and nothing 
bad will happen.  
    
6. My arms and legs shake and tremble.      
7. I am bothered by headaches neck and back 
pain. 
    
8. I feel weak and get tired easily.      
9. I feel calm and can sit still easily.     
10. I can feel my heart beating fast.      
11. I am bothered by dizzy spells.      
12. I have fainting spells or feel like it     
13. I can breathe in and out easily.      
14. I get feelings of numbness and tingling in 
my fingers & toes 
    
15. I am bothered by stomach aches or 
indigestion.  
    
16. I have to empty my bladder often     
17. My hands are usually dry and warm.      
18. My face gets hot and blushes     
19. I fall asleep easily and get a good night's 
rest. 
    










4 Adapted from Psychosomatics, 12/6, William W.K. Zung, A Rating Instrument for Anxiety Disorders, 371-
379,1971, with permission from Elsevier 
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APPENDIX 3: PATIENT HEALTH QUESTIONNAIRE-9 
 
Nine Symptom Checklist5 
Over the last 2 weeks, how often have you been 












1. Little interest or pleasure in doing things     
2. Feeling down, depressed, or hopeless     
3. Trouble falling or staying asleep or sleeping too 
much 4. Feeling tired or having little energy 
    
     
5. Poor appetite or overeating     
6. Feeling bad about yourself – or that you are a 
failure or have let yourself or your family down 
    
7. Trouble concentrating on things, such as reading 
the newspaper or watching television 
    
8. Moving or speaking so slowly that other people 
could have noticed? Or the opposite – being so 
fidgety or restless that you have been moving around 
a lot more than usual 
    
9. Thoughts that you would be better off dead or of 
hurting yourself in some way 
    
 
If you checked off any problems, how difficult have these problems made it for you to do your 
work, take care of things at home, or get along with other people? 
 
















5 Adapted by permission from Springer Nature: Springer, Journal of General Internal Medicine, The PHQ-9, Dr. 
Kurt Kroenke MD et al., 2001 
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APPENDIX 4: PTSD CHECKLIST FOR CIVILIANS 
Instruction to patient: Below is a list of problems and complaints that veterans sometimes have in 
response to stressful life experiences. Please read each one carefully, put an “X” in the box to 
indicate how much you have been bothered by that problem in the last month.6 
 
Response Not at all 
(1) 








1. Repeated, disturbing memories, 
thoughts, or images 
of a stressful experience from the 
past? 
     
2. Repeated, disturbing dreams of a 
stressful experience from the past? 
     
3. Suddenly acting or feeling as if a 
stressful experience were happening 
again (as if you were reliving it)? 
     
4. Feeling very upset when 
something reminded you of a 
stressful experience from the past? 
     
5. Having physical reactions (e.g., 
heart pounding, trouble breathing, or 
sweating) when something reminded 
you of a stressful experience from 
the past?  
     
6. Avoid thinking about or talking 
about a stressful experience from the 
past or avoid having feelings related 
to it? 
     
7. Avoid activities or situations 
because they remind you of a 
stressful experience from the past?  
     
8.Trouble remembering important 
parts of a stressful experience from 
the past? 
     
9.Loss of interest in things that you 
used to enjoy? 
     
10. Feeling distant or cut off from 
other people?  
     
11. Feeling emotionally numb or 
being unable to have loving feelings 
for those close to you?  









12. Feeling as if your future will 
somehow be cut short? 
     
13. Trouble falling or staying asleep?      
14. Feeling irritable or having angry 
outbursts? 
     
15. Having difficulty concentrating?      
16. Being “super alert” or watchful 
on guard?  
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APPENDIX 8: FLOWCHART OF PARTICIPANT RECRUITMENT INCLUDING ICD PATIENTS, 
PARTNERS, AND NEGATIVE RELATIVES 
 
 
